News | Stroke | February 02, 2026

Brainomix Launches Next Generation Stroke AI Platform

Debuting at the International Stroke Conference, the Brainomix 360 Next Generation platform includes automated net water uptake, a quantitative imaging marker increasingly discussed for assessing early tissue injury and edema severity.

Brainomix Launches Next Generation Stroke AI Platform with Novel Net Water Uptake Technology

Feb. 2, 2026 — Brainomix, a provider of AI-powered imaging tools in stroke and lung fibrosis, is introducing its new Brainomix 360 Next Generation platform at the International Stroke Conference (ISC), taking place Feb. 4-6, 2026, in New Orleans.

The new platform and feature upgrade provides a net water uptake (NWU) capability using routine non-contrast CT (NCCT) scans, as well as an award-winning user experience. The company will also present five abstracts, including an oral presentation, highlighting the value and impact of Brainomix 360 Stroke, further demonstrating its extensive evidence base.

Brainomix 360 Stroke Next Generation sets a new benchmark for user experience and innovation, having recently been honored with the prestigious Red Dot Design Award. With enhanced DICOM viewing capabilities and AI-driven, patient-specific insights, the platform supports streamlined workflows that enable fast, confident and informed decision-making.

Brainomix's AI algorithms now also include a regulatory cleared, net water uptake feature. Fully automated, the percentage-based NWU output extends Brainomix's leadership in simple imaging, unlocking expert-level insights from routine non-contrast CT scans to support improved treatment and transfer decisions.

Dr. George Harston, Chief Medical and Innovation Officer at Brainomix and Consultant Stroke Physician at Oxford University Hospitals, said: "We are delighted to introduce this latest innovation in stroke AI imaging, building on our expertise in universally available CT imaging. The automated net water uptake output complements Brainomix's unique ischemic core volume and e-ASPECTS features to provide clinicians across all hospital settings with deeper insights into stroke injury using a routine non-contrast CT scan. Emerging evidence is increasingly highlighting NWU as a vital imaging biomarker to inform treatment decisions and improve prognostication in the most severe strokes. In a world where stroke patients are missing out on effective treatments due to clinical uncertainty, we hope this latest advance can improve the confidence of physicians, even when treating the most severe strokes."

Three of the abstracts being presented at ISC have received the Paul Dudley White International Scholar Award, recognizing authors of the highest-ranked accepted abstracts from across the world.

Building on Brainomix's rich academic heritage and extensive global research network, these latest studies include:

  • A national cost-effectiveness analysis which showed that widespread adoption of Brainomix 360 Stroke could significantly increase rates of thrombolysis and thrombectomy, delivering improved functional outcomes, better long-term health quality, and a net monetary benefit.
  • Validation of the imaging foundation model to automate follow up infarct volume (FIV) segmentation.
  • The prospective performance validation of Brainomix 360 Triage LVO.
  • The clinical impact of collateral circulation dynamics during inter-hospital transfer.
  • A novel approach to enhance the detection of stroke mimics.

More details about these abstracts can be found here.

 


Related Content

News | FDA

Jan. 13, 2026 – Innovative Health, Inc. has received its 50th clearance from FDA to reprocess single-use medical devices ...

Home January 15, 2026
Home
News | FDA

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

Home January 12, 2026
Home
News | FDA

Jan. 6, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the FDA approval of the Gore Viabahn ...

Home January 06, 2026
Home
News | FDA

Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt ...

Home January 05, 2026
Home
News | FDA

Dec. 18, 2025 — Huxley Medical has announced the SANSA home sleep apnea test has received regulatory clearance from the ...

Home December 19, 2025
Home
News | FDA

Dec. 18, 2025 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer ...

Home December 18, 2025
Home
News | FDA

Dec. 15, 2025 — HeartSciences Inc., a healthcare information technology company advancing the use of ECG/EKGs through ...

Home December 16, 2025
Home
News | FDA

Nov. 25, 2025 — Remington Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance and announced ...

Home December 09, 2025
Home
News | FDA

Dec. 3, 2025 — Atraverse Medical, a medical device company developing next-generation left-heart access technology, has ...

Home December 05, 2025
Home
News | FDA

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA ...

Home December 01, 2025
Home
Subscribe Now